crystal51 / Shutterstock.com
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
On June 1, 2021, the fourth amendment of the Chinese patent law went into effect. The amendment contains generally applicable provisions and makes specific changes to design patent law and Life Science-related patents.
Alongside this, the Chinese National Intellectual Property Administration (CNIPA) issued revised patentability guidelines in January 2021 directed to patent prosecution in the Life Sciences.
Fourth amendment – linkage system
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Patents, life sciences, litigation, CNIPA, design law, Hatch Waxman, biologics, medical use, statutory damages, novelty, invention